US FDA’s Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication

por Echols, Roger M, Nagata, Tsutae
Publicado 2021

Utilization of Colistin Versus β-Lactam and β-Lactamase Inhibitor Agents in Relation to Acute Kidney Injury in Patients with Severe Gram-Negative Infections

por Doremus, Casey, Marcella, Stephen W., Cai, Bin, Echols, Roger M.
Publicado 2021

Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens – The International, Multicenter, Randomized,...

por Bassetti, Matteo, Ariyasu, Mari, Binkowitz, Bruce, Nagata, Tsutae Den, Echols, Roger M, Matsunaga, Yuko, Toyoizumi, Kiichiro, Doi, Yohei
Publicado 2019

Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance...

por Rex, John H, Talbot, George H, Goldberger, Mark J, Eisenstein, Barry I, Echols, Roger M, Tomayko, John F, Dudley, Michael N, Dane, Aaron
Publicado 2017